Top Markets
Coin of the day
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Rankning i aktier #29609
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Aktiekurs
$0.12715583
Marknadsvärde
$20.73M
Förändring (1 dag)
2.49%
Förändring (1 år)
-36.91%
Land
FR
Handel GenSight Biologics S.A. (SIGHT)

Kategori

Aktiekurshistorik för GenSight Biologics S.A. (SIGHT)
Högsta slutkurs: $0.11 den 2026-08-01

Lägsta slutkurs: $8.93 den 2016-07-01
Aktiekurshistorik för GenSight Biologics S.A. från 2016 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) 0.84%
2025 -61.96%
2024 -40.41%
2023 -85.79%
2022 -40.62%
2021 -23.84%
2020 252.34%
2019 -43.91%
2018 -36.71%
2017 -20.44%
2016 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$527.89 35.09%
US
$996.61 51.72%
NL
$117.42 -19.34%
AU
$749.90 8.10%
CH
$1.07K -5.58%
KR